Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL-Reference-Cited by-同舟云学术

Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL

Published:2002-07-31 Issue:8 Volume:16 Page:1432-1436
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

van der Velden VHJ,Jacobs DCH,Wijkhuijs AJM,Comans-Bitter WM,Willemse MJ,Hählen K,Kamps WA,van Wering ER,van Dongen JJM

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2402636.pdf

Reference28 articles.

1. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group N Engl J Med 1998 339: 591–598

2. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, Sandlund JT, Rivera GK, Rubnitz JE, Ribeiro RC, Pui CH, Campana D . Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia Blood 2000 96: 2691–2696

3. van Dongen JJ, Seriu T, Panzer-Grmayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR . Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 1998 352: 1731–1738

4. Panzer-Grmayer ER, Schneider M, Panzer S, Fasching K, Gadner H . Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia Blood 2000 95: 790–794

5. Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ, Jones CG, Rowbottom AW, Hunt LP, Green AF, Clarke E, Lankester AW, Cornish JM, Pamphilon DH, Steward CG, Oakhill A . Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia Blood 1998 92: 4072–4079

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications;Current Hematologic Malignancy Reports;2024-06-18

2. Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia;Haematologica;2024-05-10

3. Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy;Chinese Medical Journal;2023-12-26

4. How to Manage Philadelphia-Positive Acute Lymphoblastic Leukemia in Resource-Constrained Settings;Cancers;2023-12-10

5. Liquid biopsies and minimal residual disease in lymphoid malignancies;Frontiers in Oncology;2023-05-09